Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Insulin-Like Growth Factor I, Resistance To 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × dalotuzumab × Clear all
NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡